PATENT REGISTER | |||||||||||||||||||
A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2019/007 | |||||||||||||||||||
Status | Granted | Patent No. | 2649086 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Application No. | 11846757.0 | Date of Filing | 09/12/2011 | ||||||||||||||||
Date Grant Published | 19/07/2017 | Application Published | 16/10/2013 | ||||||||||||||||
Title of Invention | USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER | ||||||||||||||||||
Priority |
|
||||||||||||||||||
Inventors |
JUNE, Carl, H. LEVINE, Bruce, L. PORTER, David, L. KALOS, Michael, D. MILONE, Michael C. |
||||||||||||||||||
Current Proprietor |
The Trustees of The University of Pennsylvania Center for Technology Transfer 3160 Chestnut Street, Suite 200 Philadelphia PA 19104-6283 UNITED STATES OF AMERICA |
||||||||||||||||||
Address for service |
Kilburn & Strode LLP Lacon London 84 Theobalds Rd London WC1X 8NL UNITED KINGDOM |
||||||||||||||||||
Renewal Fees |
|
||||||||||||||||||
Publication Language | English | ||||||||||||||||||
Translation Received Date | |||||||||||||||||||
20/07/2017 | Divisional Application number: 16199372.0 Date of receipt: 17/11/2016 | ||||||||||||||||||
20/07/2017 | Divisional Application number: 17153799.6 Date of receipt: 30/01/2017 | ||||||||||||||||||
12/01/2018 | Address for Service recorded as Kilburn & Strode LLP, Lacon London, 84 Theobalds Rd, London WC1X 8NL, United Kingdom received on 04/01/2018. | ||||||||||||||||||
22/02/2019 | Request for grant a Supplementary Protection Certificate, citing Patent number 2649086 as the relevant basic patent, in respect of the product Tisagenlecleucel filed on 15/02/2019. Reference number of request is 2019/007. | ||||||||||||||||||
15/01/2020 | Supplementary Protection Certificate Number 2019/007, having an expiry date of 26/08/2033 granted on 15/01/2020. |